On 27 December 2025, Medical Dialogues reported that Aurobindo Pharma’s wholly-owned subsidiary, CuraTeQ, had terminated its agreement with US-based BioFactura Inc regarding BFI-751, biosimilar to Janssen’s/J&J’s Stelara® (ustekinumab). The termination is said to have been by consent and to have followed a strategic review of CuraTeQ’s portfolio prioritisation efforts.
Under the agreement before its termination, CuraTeQ had global manufacturing rights and an exclusive licence to commercialise BFI-751, in all major ‘regulated’ markets including the US, EU, UK, Canada, ANZ.
CuraTeQ remains actively involved in the development of biosimilars, announcing positive results from its Phase 3 trial of BP16, biosimilar to Amgen’s Prolia® (denosumab) in September 2025. According to that announcement, CuraTeQ plans to begin regulatory submissions for BP16 in the EU, US, and other key regions from January 2026. Earlier in July 2025, The Economic Times reported that CuraTeq had received marketing approval from the European Commission for Dazublys®, biosimilar to Roche/Genentech’s Herceptin® (trastuzumab).